Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13075-015-0778-z http://scihub22266oqcxt.onion/10.1186/s13075-015-0778-z C4576403!4576403 !26387933     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26387933 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Arthritis+Res+Ther 2015 ; 17 (1 ): 262 Nephropedia Template TP {{tp|p=26387933 |t=2015. Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment |pdf=|usr=}}{{26387933 }} gab.com Text Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment JO: Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=26387933 #FOAvip INTRODUCTION: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or cyclophosphamide treatment from those for whom treatment failed in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. METHODS: Clinical and flow cytometry data from the RAVE trial were downloaded from the Immunology Database and Analysis Portal and Immune Tolerance Network TrialShare public repositories. Flow cytometry data were analyzed using validated automated gating and joined with clinical data. Lymphocyte and granulocyte populations were measured in patients who achieved or failed to achieve remission. RESULTS: There was no difference in lymphocyte subsets and treatment outcome with either treatment. We defined a Granularity Index (GI) that measures the difference between the percentage of hypergranular and hypogranular granulocytes. We found that rituximab-treated patients who achieved remission had a significantly higher GI at baseline than those who did not (p?=?0.0085) and that this pattern was reversed in cyclophosphamide-treated patients (p?=?0.037). We defined optimal cutoff values of the GI using the Youden index. Cyclophosphamide was superior to rituximab in inducing remission in patients with GI below -9.25% (67% vs. 30%, respectively; p?=?0.033), whereas rituximab was superior to cyclophosphamide for patients with GI greater than 47.6% (83% vs. 33%, respectively; p?=?0.0002). CONCLUSIONS: We identified distinct subsets of granulocytes found at baseline in patients with AAV that predicted whether they were more likely to achieve remission with cyclophosphamide or rituximab. Profiling patients on the basis of the GI may lead to more successful trials and therapeutic courses in AAV. TRIAL REGISTRATION: ClinicalTrials.gov identifier (for original study from which data were obtained): NCT00104299 . Date of registration: 24 February 2005. Twit Text FOAVip Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment ????Arthritis Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=26387933 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26387933 #FOAvip English Wikipedia <ref>{{Cite pmid|26387933 }}</ref> Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment #MMPMID26387933 Nasrallah M ; Pouliot Y ; Hartmann B ; Dunn P ; Thomson E ; Wiser J ; Butte AJ Arthritis Res Ther 2015[Sep]; 17 (1 ): 262 PMID26387933 show ga INTRODUCTION: In the present study, we sought to identify markers in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that distinguish those achieving remission at 6 months following rituximab or cyclophosphamide treatment from those for whom treatment failed in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. METHODS: Clinical and flow cytometry data from the RAVE trial were downloaded from the Immunology Database and Analysis Portal and Immune Tolerance Network TrialShare public repositories. Flow cytometry data were analyzed using validated automated gating and joined with clinical data. Lymphocyte and granulocyte populations were measured in patients who achieved or failed to achieve remission. RESULTS: There was no difference in lymphocyte subsets and treatment outcome with either treatment. We defined a Granularity Index (GI) that measures the difference between the percentage of hypergranular and hypogranular granulocytes. We found that rituximab-treated patients who achieved remission had a significantly higher GI at baseline than those who did not (p?=?0.0085) and that this pattern was reversed in cyclophosphamide-treated patients (p?=?0.037). We defined optimal cutoff values of the GI using the Youden index. Cyclophosphamide was superior to rituximab in inducing remission in patients with GI below -9.25% (67% vs. 30%, respectively; p?=?0.033), whereas rituximab was superior to cyclophosphamide for patients with GI greater than 47.6% (83% vs. 33%, respectively; p?=?0.0002). CONCLUSIONS: We identified distinct subsets of granulocytes found at baseline in patients with AAV that predicted whether they were more likely to achieve remission with cyclophosphamide or rituximab. Profiling patients on the basis of the GI may lead to more successful trials and therapeutic courses in AAV. TRIAL REGISTRATION: ClinicalTrials.gov identifier (for original study from which data were obtained): NCT00104299 . Date of registration: 24 February 2005. |Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy/*immunology [MESH] |Biomarkers/*blood [MESH] |Female [MESH] |Flow Cytometry [MESH] |Granulocytes/*immunology [MESH] |Humans [MESH] |Immunologic Factors/*therapeutic use [MESH] |Male [MESH] |Middle Aged [MESH] |Remission Induction [MESH] |Rituximab/*therapeutic use [MESH]Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identi(epmc).pdf DeepDyve Pubget Overpricing